Elisa Brighenti

Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility?

D. Treré, M. Derenzini, E. Brighenti, 2015, Oncotarget.

Selective inhibition of rRNA transcription downregulates E2F-1: a new p53-independent mechanism linking cell growth to cell proliferation

G. Mazzini, L. Montanaro, D. Treré, 2011, Journal of Cell Science.

The p53‐mediated sensitivity of cancer cells to chemotherapeutic agents is conditioned by the status of the retinoblastoma protein

L. Montanaro, D. Treré, M. Derenzini, 2009, The Journal of pathology.

High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy.

L. Montanaro, D. Treré, M. Derenzini, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade.

S. Laufer, M. Bonafè, E. Brighenti, 2008, Carcinogenesis.

The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells

L. Montanaro, D. Treré, M. Derenzini, 2011, Oncogene.

Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate

L. Montanaro, D. Treré, M. Derenzini, 2016, Oncotarget.

Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer

G. Liguori, L. Montanaro, D. Treré, 2014, Oncogene.